Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 2,250

Share on StockTwits

Hikma Pharmaceuticals (LON:HIK) had its price objective raised by Citigroup from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) in a research report sent to investors on Wednesday, October 3rd. Citigroup currently has a buy rating on the stock.

A number of other research analysts have also issued reports on the company. Peel Hunt restated an add rating on shares of Hikma Pharmaceuticals in a research report on Tuesday, September 4th. Barclays reissued an underweight rating on shares of Hikma Pharmaceuticals in a research note on Monday, September 17th. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Finally, Numis Securities reissued a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 1,346.89 ($17.60).

Shares of HIK traded up GBX 4 ($0.05) during mid-day trading on Wednesday, hitting GBX 1,787.50 ($23.36). The stock had a trading volume of 408,615 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($10.64) and a fifty-two week high of GBX 2,346 ($30.65).

The company also recently announced a dividend, which was paid on Friday, September 21st. Shareholders of record on Thursday, August 23rd were paid a $0.12 dividend. The ex-dividend date of this dividend was Thursday, August 23rd. This represents a yield of 0.53%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Story: Understanding Analyst Recommendations

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.